nodes	percent_of_prediction	percent_of_DWPC	metapath
Codeine—osteoarthritis—Prednisone—psoriasis	0.469	1	CpDpCtD
Codeine—UGT2B7—Mycophenolic acid—psoriasis	0.0969	0.235	CbGbCtD
Codeine—UGT2B7—Mycophenolate mofetil—psoriasis	0.0542	0.132	CbGbCtD
Codeine—CYP3A5—Beclomethasone—psoriasis	0.0358	0.087	CbGbCtD
Codeine—CYP2D6—Hydroxyurea—psoriasis	0.0167	0.0404	CbGbCtD
Codeine—CYP3A7—Hydrocortisone—psoriasis	0.0153	0.0371	CbGbCtD
Codeine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0153	0.0371	CbGbCtD
Codeine—CYP3A7—Cyclosporine—psoriasis	0.0144	0.035	CbGbCtD
Codeine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0144	0.035	CbGbCtD
Codeine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0143	0.0346	CbGbCtD
Codeine—CYP3A4—Calcitriol—psoriasis	0.0125	0.0302	CbGbCtD
Codeine—CYP3A5—Hydrocortisone—psoriasis	0.0114	0.0278	CbGbCtD
Codeine—CYP3A5—Cyclosporine—psoriasis	0.0108	0.0263	CbGbCtD
Codeine—CYP2D6—Cholecalciferol—psoriasis	0.0101	0.0245	CbGbCtD
Codeine—CYP3A4—Methoxsalen—psoriasis	0.00969	0.0235	CbGbCtD
Codeine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00949	0.023	CbGbCtD
Codeine—CYP3A7—Dexamethasone—psoriasis	0.00949	0.023	CbGbCtD
Codeine—CYP3A5—Dexamethasone—psoriasis	0.00712	0.0173	CbGbCtD
Codeine—CYP2D6—Cyclosporine—psoriasis	0.00663	0.0161	CbGbCtD
Codeine—CYP3A4—Cholecalciferol—psoriasis	0.00642	0.0156	CbGbCtD
Codeine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00556	0.0135	CbGbCtD
Codeine—CYP3A4—Triamcinolone—psoriasis	0.00556	0.0135	CbGbCtD
Codeine—CYP3A4—Betamethasone—psoriasis	0.00477	0.0116	CbGbCtD
Codeine—CYP3A4—Prednisolone—psoriasis	0.00471	0.0114	CbGbCtD
Codeine—CYP3A4—Hydrocortisone—psoriasis	0.00446	0.0108	CbGbCtD
Codeine—CYP3A4—Prednisone—psoriasis	0.00445	0.0108	CbGbCtD
Codeine—CYP2D6—Dexamethasone—psoriasis	0.00437	0.0106	CbGbCtD
Codeine—CYP3A4—Cyclosporine—psoriasis	0.00422	0.0102	CbGbCtD
Codeine—CYP3A4—Dexamethasone—psoriasis	0.00278	0.00674	CbGbCtD
Codeine—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.000444	0.0597	CbGpPWpGaD
Codeine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000368	0.0495	CbGpPWpGaD
Codeine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000343	0.0462	CbGpPWpGaD
Codeine—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000321	0.0432	CbGpPWpGaD
Codeine—UGT2B4—Biological oxidations—CYP2S1—psoriasis	0.000255	0.0343	CbGpPWpGaD
Codeine—UGT2B4—Metapathway biotransformation—CYP2S1—psoriasis	0.000251	0.0338	CbGpPWpGaD
Codeine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000228	0.0307	CbGpPWpGaD
Codeine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000184	0.0248	CbGpPWpGaD
Codeine—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000182	0.0245	CbGpPWpGaD
Codeine—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000149	0.0201	CbGpPWpGaD
Codeine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000149	0.0201	CbGpPWpGaD
Codeine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000133	0.0179	CbGpPWpGaD
Codeine—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000131	0.0177	CbGpPWpGaD
Codeine—UGT2B7—Biological oxidations—CYP2S1—psoriasis	0.000116	0.0156	CbGpPWpGaD
Codeine—UGT2B7—Metapathway biotransformation—CYP2S1—psoriasis	0.000114	0.0154	CbGpPWpGaD
Codeine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000108	0.0145	CbGpPWpGaD
Codeine—OPRD1—G alpha (i) signalling events—HCAR2—psoriasis	0.000107	0.0144	CbGpPWpGaD
Codeine—Erythema—Dexamethasone—psoriasis	0.0001	0.000896	CcSEcCtD
Codeine—Anorexia—Mycophenolate mofetil—psoriasis	0.0001	0.000896	CcSEcCtD
Codeine—Dermatitis—Hydroxyurea—psoriasis	0.0001	0.000896	CcSEcCtD
Codeine—Hallucination—Prednisone—psoriasis	9.97e-05	0.000892	CcSEcCtD
Codeine—Malaise—Triamcinolone—psoriasis	9.96e-05	0.000891	CcSEcCtD
Codeine—Anxiety—Hydrocortisone—psoriasis	9.95e-05	0.00089	CcSEcCtD
Codeine—Vertigo—Triamcinolone—psoriasis	9.92e-05	0.000887	CcSEcCtD
Codeine—Syncope—Triamcinolone—psoriasis	9.9e-05	0.000886	CcSEcCtD
Codeine—Discomfort—Hydrocortisone—psoriasis	9.86e-05	0.000882	CcSEcCtD
Codeine—Hypotension—Mycophenolate mofetil—psoriasis	9.81e-05	0.000878	CcSEcCtD
Codeine—Insomnia—Cyclosporine—psoriasis	9.74e-05	0.000871	CcSEcCtD
Codeine—Loss of consciousness—Triamcinolone—psoriasis	9.7e-05	0.000868	CcSEcCtD
Codeine—Shock—Prednisolone—psoriasis	9.64e-05	0.000862	CcSEcCtD
Codeine—Dyspnoea—Cyclosporine—psoriasis	9.6e-05	0.000859	CcSEcCtD
Codeine—Somnolence—Cyclosporine—psoriasis	9.57e-05	0.000856	CcSEcCtD
Codeine—Convulsion—Triamcinolone—psoriasis	9.57e-05	0.000856	CcSEcCtD
Codeine—Tachycardia—Prednisolone—psoriasis	9.56e-05	0.000856	CcSEcCtD
Codeine—Asthenia—Mycophenolic acid—psoriasis	9.55e-05	0.000854	CcSEcCtD
Codeine—Insomnia—Mycophenolate mofetil—psoriasis	9.5e-05	0.00085	CcSEcCtD
Codeine—Hyperhidrosis—Prednisolone—psoriasis	9.47e-05	0.000847	CcSEcCtD
Codeine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	9.47e-05	0.0128	CbGpPWpGaD
Codeine—Nausea—Hydroxyurea—psoriasis	9.44e-05	0.000845	CcSEcCtD
Codeine—Pruritus—Mycophenolic acid—psoriasis	9.42e-05	0.000843	CcSEcCtD
Codeine—Shock—Hydrocortisone—psoriasis	9.41e-05	0.000842	CcSEcCtD
Codeine—OPRK1—G alpha (i) signalling events—HCAR2—psoriasis	9.4e-05	0.0127	CbGpPWpGaD
Codeine—Nervous system disorder—Hydrocortisone—psoriasis	9.38e-05	0.00084	CcSEcCtD
Codeine—Eye disorder—Prednisone—psoriasis	9.37e-05	0.000838	CcSEcCtD
Codeine—Dyspnoea—Mycophenolate mofetil—psoriasis	9.36e-05	0.000838	CcSEcCtD
Codeine—Decreased appetite—Cyclosporine—psoriasis	9.36e-05	0.000837	CcSEcCtD
Codeine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	9.34e-05	0.0126	CbGpPWpGaD
Codeine—Tachycardia—Hydrocortisone—psoriasis	9.34e-05	0.000836	CcSEcCtD
Codeine—Somnolence—Mycophenolate mofetil—psoriasis	9.34e-05	0.000835	CcSEcCtD
Codeine—Drowsiness—Methotrexate—psoriasis	9.33e-05	0.000835	CcSEcCtD
Codeine—Depression—Methotrexate—psoriasis	9.3e-05	0.000832	CcSEcCtD
Codeine—Flushing—Prednisone—psoriasis	9.3e-05	0.000832	CcSEcCtD
Codeine—Gastrointestinal disorder—Cyclosporine—psoriasis	9.3e-05	0.000832	CcSEcCtD
Codeine—Ill-defined disorder—Betamethasone—psoriasis	9.29e-05	0.000832	CcSEcCtD
Codeine—Ill-defined disorder—Dexamethasone—psoriasis	9.29e-05	0.000832	CcSEcCtD
Codeine—Discomfort—Triamcinolone—psoriasis	9.29e-05	0.000831	CcSEcCtD
Codeine—Fatigue—Cyclosporine—psoriasis	9.28e-05	0.000831	CcSEcCtD
Codeine—Hyperhidrosis—Hydrocortisone—psoriasis	9.25e-05	0.000828	CcSEcCtD
Codeine—Constipation—Cyclosporine—psoriasis	9.21e-05	0.000824	CcSEcCtD
Codeine—Dry mouth—Triamcinolone—psoriasis	9.19e-05	0.000822	CcSEcCtD
Codeine—Angioedema—Dexamethasone—psoriasis	9.15e-05	0.000819	CcSEcCtD
Codeine—Angioedema—Betamethasone—psoriasis	9.15e-05	0.000819	CcSEcCtD
Codeine—Decreased appetite—Mycophenolate mofetil—psoriasis	9.13e-05	0.000817	CcSEcCtD
Codeine—Anorexia—Hydrocortisone—psoriasis	9.12e-05	0.000816	CcSEcCtD
Codeine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	9.07e-05	0.000811	CcSEcCtD
Codeine—Immune system disorder—Prednisone—psoriasis	9.05e-05	0.00081	CcSEcCtD
Codeine—Malaise—Dexamethasone—psoriasis	9.03e-05	0.000808	CcSEcCtD
Codeine—Malaise—Betamethasone—psoriasis	9.03e-05	0.000808	CcSEcCtD
Codeine—Vertigo—Betamethasone—psoriasis	9e-05	0.000805	CcSEcCtD
Codeine—Vertigo—Dexamethasone—psoriasis	9e-05	0.000805	CcSEcCtD
Codeine—Syncope—Betamethasone—psoriasis	8.98e-05	0.000804	CcSEcCtD
Codeine—Syncope—Dexamethasone—psoriasis	8.98e-05	0.000804	CcSEcCtD
Codeine—Constipation—Mycophenolate mofetil—psoriasis	8.98e-05	0.000804	CcSEcCtD
Codeine—Sweating—Methotrexate—psoriasis	8.94e-05	0.0008	CcSEcCtD
Codeine—Hypotension—Hydrocortisone—psoriasis	8.94e-05	0.0008	CcSEcCtD
Codeine—Feeling abnormal—Cyclosporine—psoriasis	8.87e-05	0.000794	CcSEcCtD
Codeine—Shock—Triamcinolone—psoriasis	8.86e-05	0.000793	CcSEcCtD
Codeine—Insomnia—Prednisolone—psoriasis	8.86e-05	0.000793	CcSEcCtD
Codeine—Gastrointestinal pain—Cyclosporine—psoriasis	8.8e-05	0.000788	CcSEcCtD
Codeine—Loss of consciousness—Dexamethasone—psoriasis	8.8e-05	0.000788	CcSEcCtD
Codeine—Loss of consciousness—Betamethasone—psoriasis	8.8e-05	0.000788	CcSEcCtD
Codeine—Dizziness—Mycophenolic acid—psoriasis	8.8e-05	0.000787	CcSEcCtD
Codeine—Tachycardia—Triamcinolone—psoriasis	8.79e-05	0.000787	CcSEcCtD
Codeine—Erythema—Prednisone—psoriasis	8.72e-05	0.000781	CcSEcCtD
Codeine—Hyperhidrosis—Triamcinolone—psoriasis	8.71e-05	0.000779	CcSEcCtD
Codeine—Convulsion—Dexamethasone—psoriasis	8.68e-05	0.000777	CcSEcCtD
Codeine—Convulsion—Betamethasone—psoriasis	8.68e-05	0.000777	CcSEcCtD
Codeine—Feeling abnormal—Mycophenolate mofetil—psoriasis	8.66e-05	0.000774	CcSEcCtD
Codeine—Insomnia—Hydrocortisone—psoriasis	8.65e-05	0.000774	CcSEcCtD
Codeine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	8.59e-05	0.000768	CcSEcCtD
Codeine—Urticaria—Cyclosporine—psoriasis	8.55e-05	0.000765	CcSEcCtD
Codeine—OPRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	8.52e-05	0.0115	CbGpPWpGaD
Codeine—Abdominal pain—Cyclosporine—psoriasis	8.51e-05	0.000762	CcSEcCtD
Codeine—Body temperature increased—Cyclosporine—psoriasis	8.51e-05	0.000762	CcSEcCtD
Codeine—Anxiety—Dexamethasone—psoriasis	8.5e-05	0.00076	CcSEcCtD
Codeine—Anxiety—Betamethasone—psoriasis	8.5e-05	0.00076	CcSEcCtD
Codeine—Vomiting—Mycophenolic acid—psoriasis	8.46e-05	0.000757	CcSEcCtD
Codeine—Discomfort—Dexamethasone—psoriasis	8.43e-05	0.000754	CcSEcCtD
Codeine—Discomfort—Betamethasone—psoriasis	8.43e-05	0.000754	CcSEcCtD
Codeine—Rash—Mycophenolic acid—psoriasis	8.39e-05	0.000751	CcSEcCtD
Codeine—Dermatitis—Mycophenolic acid—psoriasis	8.38e-05	0.00075	CcSEcCtD
Codeine—Urticaria—Mycophenolate mofetil—psoriasis	8.34e-05	0.000747	CcSEcCtD
Codeine—Decreased appetite—Hydrocortisone—psoriasis	8.32e-05	0.000744	CcSEcCtD
Codeine—Abdominal pain—Mycophenolate mofetil—psoriasis	8.3e-05	0.000743	CcSEcCtD
Codeine—Body temperature increased—Mycophenolate mofetil—psoriasis	8.3e-05	0.000743	CcSEcCtD
Codeine—Urinary tract disorder—Methotrexate—psoriasis	8.27e-05	0.00074	CcSEcCtD
Codeine—Gastrointestinal disorder—Hydrocortisone—psoriasis	8.26e-05	0.000739	CcSEcCtD
Codeine—Fatigue—Hydrocortisone—psoriasis	8.25e-05	0.000738	CcSEcCtD
Codeine—Urethral disorder—Methotrexate—psoriasis	8.21e-05	0.000735	CcSEcCtD
Codeine—Insomnia—Triamcinolone—psoriasis	8.15e-05	0.000729	CcSEcCtD
Codeine—Ill-defined disorder—Prednisone—psoriasis	8.09e-05	0.000724	CcSEcCtD
Codeine—Feeling abnormal—Prednisolone—psoriasis	8.07e-05	0.000722	CcSEcCtD
Codeine—Visual impairment—Methotrexate—psoriasis	8.07e-05	0.000722	CcSEcCtD
Codeine—Shock—Dexamethasone—psoriasis	8.04e-05	0.00072	CcSEcCtD
Codeine—Shock—Betamethasone—psoriasis	8.04e-05	0.00072	CcSEcCtD
Codeine—Dyspnoea—Triamcinolone—psoriasis	8.03e-05	0.000719	CcSEcCtD
Codeine—Nervous system disorder—Dexamethasone—psoriasis	8.02e-05	0.000717	CcSEcCtD
Codeine—Nervous system disorder—Betamethasone—psoriasis	8.02e-05	0.000717	CcSEcCtD
Codeine—Agitation—Prednisone—psoriasis	8.02e-05	0.000717	CcSEcCtD
Codeine—Tachycardia—Dexamethasone—psoriasis	7.98e-05	0.000714	CcSEcCtD
Codeine—Tachycardia—Betamethasone—psoriasis	7.98e-05	0.000714	CcSEcCtD
Codeine—Angioedema—Prednisone—psoriasis	7.97e-05	0.000713	CcSEcCtD
Codeine—OPRM1—G alpha (i) signalling events—HCAR2—psoriasis	7.94e-05	0.0107	CbGpPWpGaD
Codeine—Hypersensitivity—Cyclosporine—psoriasis	7.93e-05	0.00071	CcSEcCtD
Codeine—CYP3A7—Biological oxidations—CYP2S1—psoriasis	7.93e-05	0.0107	CbGpPWpGaD
Codeine—Nausea—Mycophenolic acid—psoriasis	7.91e-05	0.000707	CcSEcCtD
Codeine—Hyperhidrosis—Dexamethasone—psoriasis	7.9e-05	0.000707	CcSEcCtD
Codeine—Hyperhidrosis—Betamethasone—psoriasis	7.9e-05	0.000707	CcSEcCtD
Codeine—Feeling abnormal—Hydrocortisone—psoriasis	7.89e-05	0.000706	CcSEcCtD
Codeine—Malaise—Prednisone—psoriasis	7.87e-05	0.000704	CcSEcCtD
Codeine—Vertigo—Prednisone—psoriasis	7.84e-05	0.000701	CcSEcCtD
Codeine—Eye disorder—Methotrexate—psoriasis	7.83e-05	0.0007	CcSEcCtD
Codeine—Gastrointestinal pain—Hydrocortisone—psoriasis	7.82e-05	0.0007	CcSEcCtD
Codeine—Syncope—Prednisone—psoriasis	7.82e-05	0.0007	CcSEcCtD
Codeine—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	7.82e-05	0.0105	CbGpPWpGaD
Codeine—Anorexia—Dexamethasone—psoriasis	7.79e-05	0.000697	CcSEcCtD
Codeine—Anorexia—Betamethasone—psoriasis	7.79e-05	0.000697	CcSEcCtD
Codeine—Urticaria—Prednisolone—psoriasis	7.78e-05	0.000696	CcSEcCtD
Codeine—Cardiac disorder—Methotrexate—psoriasis	7.77e-05	0.000695	CcSEcCtD
Codeine—Fatigue—Triamcinolone—psoriasis	7.77e-05	0.000695	CcSEcCtD
Codeine—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.74e-05	0.000692	CcSEcCtD
Codeine—Asthenia—Cyclosporine—psoriasis	7.73e-05	0.000691	CcSEcCtD
Codeine—OPRM1—TCR Signaling Pathway—REL—psoriasis	7.68e-05	0.0103	CbGpPWpGaD
Codeine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.67e-05	0.0103	CbGpPWpGaD
Codeine—Loss of consciousness—Prednisone—psoriasis	7.67e-05	0.000686	CcSEcCtD
Codeine—Hypotension—Betamethasone—psoriasis	7.64e-05	0.000684	CcSEcCtD
Codeine—Hypotension—Dexamethasone—psoriasis	7.64e-05	0.000684	CcSEcCtD
Codeine—Pruritus—Cyclosporine—psoriasis	7.62e-05	0.000682	CcSEcCtD
Codeine—Urticaria—Hydrocortisone—psoriasis	7.6e-05	0.00068	CcSEcCtD
Codeine—Immune system disorder—Methotrexate—psoriasis	7.56e-05	0.000677	CcSEcCtD
Codeine—Body temperature increased—Hydrocortisone—psoriasis	7.56e-05	0.000677	CcSEcCtD
Codeine—Abdominal pain—Hydrocortisone—psoriasis	7.56e-05	0.000677	CcSEcCtD
Codeine—Convulsion—Prednisone—psoriasis	7.56e-05	0.000676	CcSEcCtD
Codeine—Mediastinal disorder—Methotrexate—psoriasis	7.55e-05	0.000675	CcSEcCtD
Codeine—Asthenia—Mycophenolate mofetil—psoriasis	7.54e-05	0.000674	CcSEcCtD
Codeine—OPRK1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	7.47e-05	0.0101	CbGpPWpGaD
Codeine—Pruritus—Mycophenolate mofetil—psoriasis	7.43e-05	0.000665	CcSEcCtD
Codeine—Feeling abnormal—Triamcinolone—psoriasis	7.43e-05	0.000664	CcSEcCtD
Codeine—Anxiety—Prednisone—psoriasis	7.4e-05	0.000662	CcSEcCtD
Codeine—Insomnia—Dexamethasone—psoriasis	7.39e-05	0.000662	CcSEcCtD
Codeine—Insomnia—Betamethasone—psoriasis	7.39e-05	0.000662	CcSEcCtD
Codeine—Discomfort—Prednisone—psoriasis	7.34e-05	0.000657	CcSEcCtD
Codeine—Erythema—Methotrexate—psoriasis	7.29e-05	0.000652	CcSEcCtD
Codeine—Hypersensitivity—Prednisolone—psoriasis	7.22e-05	0.000646	CcSEcCtD
Codeine—Urticaria—Triamcinolone—psoriasis	7.16e-05	0.00064	CcSEcCtD
Codeine—Body temperature increased—Triamcinolone—psoriasis	7.12e-05	0.000637	CcSEcCtD
Codeine—Dizziness—Cyclosporine—psoriasis	7.12e-05	0.000637	CcSEcCtD
Codeine—Decreased appetite—Dexamethasone—psoriasis	7.11e-05	0.000636	CcSEcCtD
Codeine—Decreased appetite—Betamethasone—psoriasis	7.11e-05	0.000636	CcSEcCtD
Codeine—Gastrointestinal disorder—Dexamethasone—psoriasis	7.06e-05	0.000632	CcSEcCtD
Codeine—Gastrointestinal disorder—Betamethasone—psoriasis	7.06e-05	0.000632	CcSEcCtD
Codeine—Hypersensitivity—Hydrocortisone—psoriasis	7.05e-05	0.000631	CcSEcCtD
Codeine—Fatigue—Betamethasone—psoriasis	7.05e-05	0.000631	CcSEcCtD
Codeine—Fatigue—Dexamethasone—psoriasis	7.05e-05	0.000631	CcSEcCtD
Codeine—Shock—Prednisone—psoriasis	7e-05	0.000627	CcSEcCtD
Codeine—Nervous system disorder—Prednisone—psoriasis	6.98e-05	0.000625	CcSEcCtD
Codeine—Tachycardia—Prednisone—psoriasis	6.95e-05	0.000622	CcSEcCtD
Codeine—Dizziness—Mycophenolate mofetil—psoriasis	6.95e-05	0.000621	CcSEcCtD
Codeine—Hyperhidrosis—Prednisone—psoriasis	6.88e-05	0.000616	CcSEcCtD
Codeine—Asthenia—Hydrocortisone—psoriasis	6.87e-05	0.000614	CcSEcCtD
Codeine—Vomiting—Cyclosporine—psoriasis	6.85e-05	0.000613	CcSEcCtD
Codeine—Rash—Cyclosporine—psoriasis	6.79e-05	0.000607	CcSEcCtD
Codeine—Anorexia—Prednisone—psoriasis	6.79e-05	0.000607	CcSEcCtD
Codeine—Dermatitis—Cyclosporine—psoriasis	6.78e-05	0.000607	CcSEcCtD
Codeine—Pruritus—Hydrocortisone—psoriasis	6.77e-05	0.000606	CcSEcCtD
Codeine—Ill-defined disorder—Methotrexate—psoriasis	6.76e-05	0.000605	CcSEcCtD
Codeine—Feeling abnormal—Betamethasone—psoriasis	6.74e-05	0.000603	CcSEcCtD
Codeine—Feeling abnormal—Dexamethasone—psoriasis	6.74e-05	0.000603	CcSEcCtD
Codeine—Gastrointestinal pain—Betamethasone—psoriasis	6.69e-05	0.000598	CcSEcCtD
Codeine—Gastrointestinal pain—Dexamethasone—psoriasis	6.69e-05	0.000598	CcSEcCtD
Codeine—Vomiting—Mycophenolate mofetil—psoriasis	6.68e-05	0.000598	CcSEcCtD
Codeine—Hypersensitivity—Triamcinolone—psoriasis	6.64e-05	0.000594	CcSEcCtD
Codeine—Rash—Mycophenolate mofetil—psoriasis	6.62e-05	0.000593	CcSEcCtD
Codeine—Dermatitis—Mycophenolate mofetil—psoriasis	6.62e-05	0.000592	CcSEcCtD
Codeine—OPRD1—Peptide ligand-binding receptors—CCL20—psoriasis	6.6e-05	0.00889	CbGpPWpGaD
Codeine—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	6.6e-05	0.00889	CbGpPWpGaD
Codeine—Malaise—Methotrexate—psoriasis	6.57e-05	0.000588	CcSEcCtD
Codeine—Vertigo—Methotrexate—psoriasis	6.55e-05	0.000586	CcSEcCtD
Codeine—Urticaria—Dexamethasone—psoriasis	6.49e-05	0.000581	CcSEcCtD
Codeine—Urticaria—Betamethasone—psoriasis	6.49e-05	0.000581	CcSEcCtD
Codeine—OPRD1—GPCR ligand binding—HCAR2—psoriasis	6.49e-05	0.00874	CbGpPWpGaD
Codeine—Dizziness—Prednisolone—psoriasis	6.48e-05	0.00058	CcSEcCtD
Codeine—Asthenia—Triamcinolone—psoriasis	6.46e-05	0.000578	CcSEcCtD
Codeine—Body temperature increased—Betamethasone—psoriasis	6.46e-05	0.000578	CcSEcCtD
Codeine—Abdominal pain—Betamethasone—psoriasis	6.46e-05	0.000578	CcSEcCtD
Codeine—Abdominal pain—Dexamethasone—psoriasis	6.46e-05	0.000578	CcSEcCtD
Codeine—Body temperature increased—Dexamethasone—psoriasis	6.46e-05	0.000578	CcSEcCtD
Codeine—UGT2B7—NRF2 pathway—TGFA—psoriasis	6.46e-05	0.0087	CbGpPWpGaD
Codeine—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	6.46e-05	0.0087	CbGpPWpGaD
Codeine—Insomnia—Prednisone—psoriasis	6.44e-05	0.000576	CcSEcCtD
Codeine—Nausea—Cyclosporine—psoriasis	6.4e-05	0.000572	CcSEcCtD
Codeine—Pruritus—Triamcinolone—psoriasis	6.37e-05	0.00057	CcSEcCtD
Codeine—Dizziness—Hydrocortisone—psoriasis	6.33e-05	0.000566	CcSEcCtD
Codeine—Convulsion—Methotrexate—psoriasis	6.32e-05	0.000565	CcSEcCtD
Codeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	6.32e-05	0.00851	CbGpPWpGaD
Codeine—Nausea—Mycophenolate mofetil—psoriasis	6.24e-05	0.000558	CcSEcCtD
Codeine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	6.19e-05	0.00834	CbGpPWpGaD
Codeine—Decreased appetite—Prednisone—psoriasis	6.19e-05	0.000554	CcSEcCtD
Codeine—Rash—Prednisolone—psoriasis	6.18e-05	0.000553	CcSEcCtD
Codeine—Dermatitis—Prednisolone—psoriasis	6.17e-05	0.000552	CcSEcCtD
Codeine—Fatigue—Prednisone—psoriasis	6.14e-05	0.000549	CcSEcCtD
Codeine—Discomfort—Methotrexate—psoriasis	6.13e-05	0.000549	CcSEcCtD
Codeine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	6.11e-05	0.00823	CbGpPWpGaD
Codeine—Constipation—Prednisone—psoriasis	6.09e-05	0.000545	CcSEcCtD
Codeine—Vomiting—Hydrocortisone—psoriasis	6.08e-05	0.000544	CcSEcCtD
Codeine—Rash—Hydrocortisone—psoriasis	6.03e-05	0.00054	CcSEcCtD
Codeine—Dermatitis—Hydrocortisone—psoriasis	6.03e-05	0.000539	CcSEcCtD
Codeine—Confusional state—Methotrexate—psoriasis	6e-05	0.000537	CcSEcCtD
Codeine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	5.97e-05	0.00805	CbGpPWpGaD
Codeine—Dizziness—Triamcinolone—psoriasis	5.96e-05	0.000533	CcSEcCtD
Codeine—OPRM1—IL4-mediated signaling events—IL10—psoriasis	5.92e-05	0.00797	CbGpPWpGaD
Codeine—Feeling abnormal—Prednisone—psoriasis	5.87e-05	0.000525	CcSEcCtD
Codeine—Asthenia—Dexamethasone—psoriasis	5.87e-05	0.000525	CcSEcCtD
Codeine—Asthenia—Betamethasone—psoriasis	5.87e-05	0.000525	CcSEcCtD
Codeine—Nervous system disorder—Methotrexate—psoriasis	5.84e-05	0.000522	CcSEcCtD
Codeine—Gastrointestinal pain—Prednisone—psoriasis	5.82e-05	0.000521	CcSEcCtD
Codeine—Nausea—Prednisolone—psoriasis	5.82e-05	0.000521	CcSEcCtD
Codeine—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	5.79e-05	0.0078	CbGpPWpGaD
Codeine—Pruritus—Betamethasone—psoriasis	5.78e-05	0.000518	CcSEcCtD
Codeine—Pruritus—Dexamethasone—psoriasis	5.78e-05	0.000518	CcSEcCtD
Codeine—OPRM1—IL4-mediated signaling events—IL4—psoriasis	5.76e-05	0.00775	CbGpPWpGaD
Codeine—Hyperhidrosis—Methotrexate—psoriasis	5.75e-05	0.000515	CcSEcCtD
Codeine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	5.73e-05	0.00772	CbGpPWpGaD
Codeine—Vomiting—Triamcinolone—psoriasis	5.73e-05	0.000513	CcSEcCtD
Codeine—OPRK1—GPCR ligand binding—HCAR2—psoriasis	5.69e-05	0.00767	CbGpPWpGaD
Codeine—Nausea—Hydrocortisone—psoriasis	5.68e-05	0.000509	CcSEcCtD
Codeine—Rash—Triamcinolone—psoriasis	5.68e-05	0.000508	CcSEcCtD
Codeine—Dermatitis—Triamcinolone—psoriasis	5.68e-05	0.000508	CcSEcCtD
Codeine—Anorexia—Methotrexate—psoriasis	5.67e-05	0.000507	CcSEcCtD
Codeine—Urticaria—Prednisone—psoriasis	5.66e-05	0.000506	CcSEcCtD
Codeine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	5.65e-05	0.00762	CbGpPWpGaD
Codeine—Body temperature increased—Prednisone—psoriasis	5.63e-05	0.000504	CcSEcCtD
Codeine—Abdominal pain—Prednisone—psoriasis	5.63e-05	0.000504	CcSEcCtD
Codeine—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	5.57e-05	0.0075	CbGpPWpGaD
Codeine—Hypotension—Methotrexate—psoriasis	5.56e-05	0.000497	CcSEcCtD
Codeine—Dizziness—Betamethasone—psoriasis	5.41e-05	0.000484	CcSEcCtD
Codeine—Dizziness—Dexamethasone—psoriasis	5.41e-05	0.000484	CcSEcCtD
Codeine—Insomnia—Methotrexate—psoriasis	5.38e-05	0.000482	CcSEcCtD
Codeine—Nausea—Triamcinolone—psoriasis	5.35e-05	0.000479	CcSEcCtD
Codeine—Dyspnoea—Methotrexate—psoriasis	5.3e-05	0.000475	CcSEcCtD
Codeine—Somnolence—Methotrexate—psoriasis	5.29e-05	0.000473	CcSEcCtD
Codeine—Hypersensitivity—Prednisone—psoriasis	5.25e-05	0.000469	CcSEcCtD
Codeine—Vomiting—Betamethasone—psoriasis	5.2e-05	0.000465	CcSEcCtD
Codeine—Vomiting—Dexamethasone—psoriasis	5.2e-05	0.000465	CcSEcCtD
Codeine—Decreased appetite—Methotrexate—psoriasis	5.17e-05	0.000463	CcSEcCtD
Codeine—Rash—Dexamethasone—psoriasis	5.15e-05	0.000461	CcSEcCtD
Codeine—Rash—Betamethasone—psoriasis	5.15e-05	0.000461	CcSEcCtD
Codeine—Dermatitis—Betamethasone—psoriasis	5.15e-05	0.000461	CcSEcCtD
Codeine—Dermatitis—Dexamethasone—psoriasis	5.15e-05	0.000461	CcSEcCtD
Codeine—Gastrointestinal disorder—Methotrexate—psoriasis	5.14e-05	0.00046	CcSEcCtD
Codeine—Fatigue—Methotrexate—psoriasis	5.13e-05	0.000459	CcSEcCtD
Codeine—UGT2B4—Metabolism—NDUFA5—psoriasis	5.12e-05	0.0069	CbGpPWpGaD
Codeine—Asthenia—Prednisone—psoriasis	5.11e-05	0.000457	CcSEcCtD
Codeine—Pruritus—Prednisone—psoriasis	5.04e-05	0.000451	CcSEcCtD
Codeine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	5.02e-05	0.00676	CbGpPWpGaD
Codeine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	4.95e-05	0.00667	CbGpPWpGaD
Codeine—Feeling abnormal—Methotrexate—psoriasis	4.9e-05	0.000439	CcSEcCtD
Codeine—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	4.89e-05	0.00659	CbGpPWpGaD
Codeine—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	4.88e-05	0.00658	CbGpPWpGaD
Codeine—Gastrointestinal pain—Methotrexate—psoriasis	4.87e-05	0.000435	CcSEcCtD
Codeine—Nausea—Dexamethasone—psoriasis	4.86e-05	0.000434	CcSEcCtD
Codeine—Nausea—Betamethasone—psoriasis	4.86e-05	0.000434	CcSEcCtD
Codeine—OPRM1—GPCR ligand binding—HCAR2—psoriasis	4.81e-05	0.00648	CbGpPWpGaD
Codeine—Urticaria—Methotrexate—psoriasis	4.73e-05	0.000423	CcSEcCtD
Codeine—Dizziness—Prednisone—psoriasis	4.71e-05	0.000421	CcSEcCtD
Codeine—Abdominal pain—Methotrexate—psoriasis	4.7e-05	0.000421	CcSEcCtD
Codeine—Body temperature increased—Methotrexate—psoriasis	4.7e-05	0.000421	CcSEcCtD
Codeine—Vomiting—Prednisone—psoriasis	4.53e-05	0.000405	CcSEcCtD
Codeine—Rash—Prednisone—psoriasis	4.49e-05	0.000402	CcSEcCtD
Codeine—Dermatitis—Prednisone—psoriasis	4.49e-05	0.000401	CcSEcCtD
Codeine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	4.43e-05	0.00596	CbGpPWpGaD
Codeine—Hypersensitivity—Methotrexate—psoriasis	4.38e-05	0.000392	CcSEcCtD
Codeine—UGT2B4—Metabolism—CYP2S1—psoriasis	4.36e-05	0.00587	CbGpPWpGaD
Codeine—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	4.34e-05	0.00585	CbGpPWpGaD
Codeine—Asthenia—Methotrexate—psoriasis	4.27e-05	0.000382	CcSEcCtD
Codeine—Nausea—Prednisone—psoriasis	4.23e-05	0.000378	CcSEcCtD
Codeine—Pruritus—Methotrexate—psoriasis	4.21e-05	0.000377	CcSEcCtD
Codeine—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	4.13e-05	0.00556	CbGpPWpGaD
Codeine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	4.08e-05	0.00549	CbGpPWpGaD
Codeine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	4.02e-05	0.00542	CbGpPWpGaD
Codeine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	3.95e-05	0.00532	CbGpPWpGaD
Codeine—Dizziness—Methotrexate—psoriasis	3.93e-05	0.000352	CcSEcCtD
Codeine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	3.88e-05	0.00523	CbGpPWpGaD
Codeine—Vomiting—Methotrexate—psoriasis	3.78e-05	0.000339	CcSEcCtD
Codeine—Rash—Methotrexate—psoriasis	3.75e-05	0.000336	CcSEcCtD
Codeine—Dermatitis—Methotrexate—psoriasis	3.75e-05	0.000335	CcSEcCtD
Codeine—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	3.67e-05	0.00494	CbGpPWpGaD
Codeine—Nausea—Methotrexate—psoriasis	3.53e-05	0.000316	CcSEcCtD
Codeine—OPRD1—GPCR ligand binding—CCL20—psoriasis	3.37e-05	0.00454	CbGpPWpGaD
Codeine—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	3.37e-05	0.00454	CbGpPWpGaD
Codeine—OPRD1—Signaling by GPCR—HCAR2—psoriasis	3.33e-05	0.00449	CbGpPWpGaD
Codeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	3.28e-05	0.00442	CbGpPWpGaD
Codeine—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	3.22e-05	0.00433	CbGpPWpGaD
Codeine—OPRK1—GPCR ligand binding—CCL20—psoriasis	2.96e-05	0.00398	CbGpPWpGaD
Codeine—OPRK1—Signaling by GPCR—HCAR2—psoriasis	2.92e-05	0.00393	CbGpPWpGaD
Codeine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	2.84e-05	0.00383	CbGpPWpGaD
Codeine—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	2.72e-05	0.00366	CbGpPWpGaD
Codeine—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	2.71e-05	0.00366	CbGpPWpGaD
Codeine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	2.67e-05	0.00359	CbGpPWpGaD
Codeine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	2.63e-05	0.00354	CbGpPWpGaD
Codeine—OPRM1—GPCR ligand binding—CCL20—psoriasis	2.5e-05	0.00337	CbGpPWpGaD
Codeine—OPRM1—TCR Signaling Pathway—CD4—psoriasis	2.49e-05	0.00336	CbGpPWpGaD
Codeine—OPRM1—Signaling by GPCR—HCAR2—psoriasis	2.47e-05	0.00332	CbGpPWpGaD
Codeine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	2.35e-05	0.00317	CbGpPWpGaD
Codeine—UGT2B7—Metabolism—NDUFA5—psoriasis	2.33e-05	0.00314	CbGpPWpGaD
Codeine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	2.3e-05	0.0031	CbGpPWpGaD
Codeine—OPRM1—TCR Signaling Pathway—JUN—psoriasis	2.23e-05	0.00301	CbGpPWpGaD
Codeine—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	2.15e-05	0.00289	CbGpPWpGaD
Codeine—UGT2B4—Metabolism—CARM1—psoriasis	2.13e-05	0.00287	CbGpPWpGaD
Codeine—UGT2B7—Metabolism—CYP2S1—psoriasis	1.98e-05	0.00267	CbGpPWpGaD
Codeine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.98e-05	0.00267	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—HCAR2—psoriasis	1.97e-05	0.00265	CbGpPWpGaD
Codeine—OPRD1—GPCR downstream signaling—CCL20—psoriasis	1.91e-05	0.00257	CbGpPWpGaD
Codeine—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	1.78e-05	0.0024	CbGpPWpGaD
Codeine—OPRD1—Signaling by GPCR—CCL20—psoriasis	1.73e-05	0.00233	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—HCAR2—psoriasis	1.73e-05	0.00232	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—TAGAP—psoriasis	1.71e-05	0.0023	CbGpPWpGaD
Codeine—OPRK1—GPCR downstream signaling—CCL20—psoriasis	1.67e-05	0.00225	CbGpPWpGaD
Codeine—CYP3A7—Metabolism—NDUFA5—psoriasis	1.6e-05	0.00215	CbGpPWpGaD
Codeine—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	1.56e-05	0.00211	CbGpPWpGaD
Codeine—OPRK1—Signaling by GPCR—CCL20—psoriasis	1.52e-05	0.00204	CbGpPWpGaD
Codeine—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	1.5e-05	0.00203	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—TAGAP—psoriasis	1.5e-05	0.00201	CbGpPWpGaD
Codeine—SLC22A1—Metabolism—NDUFA5—psoriasis	1.48e-05	0.002	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—HCAR2—psoriasis	1.46e-05	0.00196	CbGpPWpGaD
Codeine—OPRM1—GPCR downstream signaling—CCL20—psoriasis	1.41e-05	0.0019	CbGpPWpGaD
Codeine—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	1.38e-05	0.00186	CbGpPWpGaD
Codeine—CYP3A7—Metabolism—CYP2S1—psoriasis	1.36e-05	0.00183	CbGpPWpGaD
Codeine—OPRM1—TCR Signaling Pathway—IL6—psoriasis	1.35e-05	0.00182	CbGpPWpGaD
Codeine—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	1.32e-05	0.00178	CbGpPWpGaD
Codeine—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	1.32e-05	0.00178	CbGpPWpGaD
Codeine—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	1.32e-05	0.00177	CbGpPWpGaD
Codeine—UGT2B4—Metabolism—CAT—psoriasis	1.31e-05	0.00176	CbGpPWpGaD
Codeine—OPRM1—Signaling by GPCR—CCL20—psoriasis	1.28e-05	0.00173	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—TAGAP—psoriasis	1.26e-05	0.0017	CbGpPWpGaD
Codeine—SLC22A1—Metabolism—CYP2S1—psoriasis	1.26e-05	0.0017	CbGpPWpGaD
Codeine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.2e-05	0.00161	CbGpPWpGaD
Codeine—CYP3A5—Metabolism—NDUFA5—psoriasis	1.15e-05	0.00155	CbGpPWpGaD
Codeine—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	1.11e-05	0.0015	CbGpPWpGaD
Codeine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.05e-05	0.00141	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—CCL20—psoriasis	1.02e-05	0.00138	CbGpPWpGaD
Codeine—UGT2B4—Metabolism—APOE—psoriasis	1.02e-05	0.00137	CbGpPWpGaD
Codeine—CYP3A5—Metabolism—CYP2S1—psoriasis	9.8e-06	0.00132	CbGpPWpGaD
Codeine—UGT2B7—Metabolism—CARM1—psoriasis	9.69e-06	0.00131	CbGpPWpGaD
Codeine—OPRD1—GPCR ligand binding—CXCL8—psoriasis	9.1e-06	0.00123	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—CCL20—psoriasis	8.96e-06	0.00121	CbGpPWpGaD
Codeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	8.86e-06	0.00119	CbGpPWpGaD
Codeine—UGT2B4—Metabolism—PPARG—psoriasis	8.86e-06	0.00119	CbGpPWpGaD
Codeine—CYP2D6—Metabolism—NDUFA5—psoriasis	8.2e-06	0.0011	CbGpPWpGaD
Codeine—OPRK1—GPCR ligand binding—CXCL8—psoriasis	7.98e-06	0.00108	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—CCL20—psoriasis	7.57e-06	0.00102	CbGpPWpGaD
Codeine—CYP2D6—Metabolism—CYP2S1—psoriasis	6.97e-06	0.000939	CbGpPWpGaD
Codeine—OPRM1—GPCR ligand binding—CXCL8—psoriasis	6.75e-06	0.000909	CbGpPWpGaD
Codeine—CYP3A7—Metabolism—CARM1—psoriasis	6.62e-06	0.000892	CbGpPWpGaD
Codeine—SLC22A1—Metabolism—CARM1—psoriasis	6.16e-06	0.00083	CbGpPWpGaD
Codeine—UGT2B7—Metabolism—CAT—psoriasis	5.96e-06	0.000803	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—SOCS1—psoriasis	5.63e-06	0.000758	CbGpPWpGaD
Codeine—OPRD1—Signaling by GPCR—TYK2—psoriasis	5.37e-06	0.000723	CbGpPWpGaD
Codeine—CYP3A4—Metabolism—NDUFA5—psoriasis	5.36e-06	0.000722	CbGpPWpGaD
Codeine—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	5.14e-06	0.000693	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—SOCS1—psoriasis	4.93e-06	0.000665	CbGpPWpGaD
Codeine—CYP3A5—Metabolism—CARM1—psoriasis	4.79e-06	0.000645	CbGpPWpGaD
Codeine—OPRK1—Signaling by GPCR—TYK2—psoriasis	4.71e-06	0.000634	CbGpPWpGaD
Codeine—OPRD1—Signaling by GPCR—CXCL8—psoriasis	4.67e-06	0.000629	CbGpPWpGaD
Codeine—UGT2B7—Metabolism—APOE—psoriasis	4.63e-06	0.000624	CbGpPWpGaD
Codeine—CYP3A4—Metabolism—CYP2S1—psoriasis	4.56e-06	0.000614	CbGpPWpGaD
Codeine—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	4.51e-06	0.000608	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—SOCS1—psoriasis	4.17e-06	0.000562	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—APOE—psoriasis	4.15e-06	0.000559	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—LEP—psoriasis	4.15e-06	0.000559	CbGpPWpGaD
Codeine—OPRK1—Signaling by GPCR—CXCL8—psoriasis	4.1e-06	0.000552	CbGpPWpGaD
Codeine—CYP3A7—Metabolism—CAT—psoriasis	4.07e-06	0.000549	CbGpPWpGaD
Codeine—UGT2B7—Metabolism—PPARG—psoriasis	4.03e-06	0.000543	CbGpPWpGaD
Codeine—OPRM1—Signaling by GPCR—TYK2—psoriasis	3.98e-06	0.000536	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—NFKBIA—psoriasis	3.87e-06	0.000521	CbGpPWpGaD
Codeine—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	3.81e-06	0.000514	CbGpPWpGaD
Codeine—SLC22A1—Metabolism—CAT—psoriasis	3.79e-06	0.000511	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—APOE—psoriasis	3.64e-06	0.000491	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—LEP—psoriasis	3.64e-06	0.000491	CbGpPWpGaD
Codeine—OPRM1—Signaling by GPCR—CXCL8—psoriasis	3.46e-06	0.000466	CbGpPWpGaD
Codeine—CYP2D6—Metabolism—CARM1—psoriasis	3.4e-06	0.000459	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—NFKBIA—psoriasis	3.39e-06	0.000457	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—TYK2—psoriasis	3.17e-06	0.000427	CbGpPWpGaD
Codeine—CYP3A7—Metabolism—APOE—psoriasis	3.17e-06	0.000426	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—LEP—psoriasis	3.08e-06	0.000415	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—APOE—psoriasis	3.08e-06	0.000415	CbGpPWpGaD
Codeine—SLC22A1—Metabolism—APOE—psoriasis	2.95e-06	0.000397	CbGpPWpGaD
Codeine—CYP3A5—Metabolism—CAT—psoriasis	2.95e-06	0.000397	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—NFKBIA—psoriasis	2.87e-06	0.000386	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—TYK2—psoriasis	2.78e-06	0.000374	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—CXCL8—psoriasis	2.76e-06	0.000372	CbGpPWpGaD
Codeine—CYP3A7—Metabolism—PPARG—psoriasis	2.76e-06	0.000371	CbGpPWpGaD
Codeine—OPRD1—Signaling by GPCR—IL6—psoriasis	2.62e-06	0.000353	CbGpPWpGaD
Codeine—SLC22A1—Metabolism—PPARG—psoriasis	2.57e-06	0.000346	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—JUN—psoriasis	2.57e-06	0.000346	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—NFKB1—psoriasis	2.47e-06	0.000333	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—CXCL8—psoriasis	2.42e-06	0.000326	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—TYK2—psoriasis	2.35e-06	0.000316	CbGpPWpGaD
Codeine—OPRK1—Signaling by GPCR—IL6—psoriasis	2.3e-06	0.00031	CbGpPWpGaD
Codeine—CYP3A5—Metabolism—APOE—psoriasis	2.29e-06	0.000308	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—JUN—psoriasis	2.25e-06	0.000303	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—VEGFA—psoriasis	2.24e-06	0.000302	CbGpPWpGaD
Codeine—CYP3A4—Metabolism—CARM1—psoriasis	2.23e-06	0.0003	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—STAT3—psoriasis	2.22e-06	0.000299	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—NFKB1—psoriasis	2.17e-06	0.000292	CbGpPWpGaD
Codeine—CYP2D6—Metabolism—CAT—psoriasis	2.09e-06	0.000282	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—CXCL8—psoriasis	2.05e-06	0.000275	CbGpPWpGaD
Codeine—CYP3A5—Metabolism—PPARG—psoriasis	1.99e-06	0.000268	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—VEGFA—psoriasis	1.97e-06	0.000265	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—STAT3—psoriasis	1.95e-06	0.000262	CbGpPWpGaD
Codeine—OPRM1—Signaling by GPCR—IL6—psoriasis	1.94e-06	0.000262	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—JUN—psoriasis	1.9e-06	0.000256	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—NFKB1—psoriasis	1.83e-06	0.000247	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—TP53—psoriasis	1.69e-06	0.000228	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—VEGFA—psoriasis	1.66e-06	0.000224	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—STAT3—psoriasis	1.64e-06	0.000222	CbGpPWpGaD
Codeine—CYP2D6—Metabolism—APOE—psoriasis	1.63e-06	0.000219	CbGpPWpGaD
Codeine—OPRD1—Signaling Pathways—IL6—psoriasis	1.55e-06	0.000209	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—TP53—psoriasis	1.49e-06	0.0002	CbGpPWpGaD
Codeine—CYP2D6—Metabolism—PPARG—psoriasis	1.42e-06	0.000191	CbGpPWpGaD
Codeine—CYP3A4—Metabolism—CAT—psoriasis	1.37e-06	0.000184	CbGpPWpGaD
Codeine—OPRK1—Signaling Pathways—IL6—psoriasis	1.36e-06	0.000183	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—TP53—psoriasis	1.26e-06	0.000169	CbGpPWpGaD
Codeine—OPRM1—Signaling Pathways—IL6—psoriasis	1.15e-06	0.000155	CbGpPWpGaD
Codeine—CYP3A4—Metabolism—APOE—psoriasis	1.06e-06	0.000143	CbGpPWpGaD
Codeine—CYP3A4—Metabolism—PPARG—psoriasis	9.27e-07	0.000125	CbGpPWpGaD
